Image For Activity Cover
Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification (JACC CardioOncology September 2021-1)
Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification
Radiation therapy is an important component of cancer therapy for many malignancies. With improvements in cardiac-sparing techniques, radiation-induced cardiac dysfunction has decreased but remains a continued concern. In this review, we provide an overview of the evolution of radiotherapy techniques in thoracic cancers and associated reductions in cardiac risk. We also highlight data demonstrating that in some cases radiation doses to specific cardiac substructures correlate with cardiac toxicities and/or survival beyond mean heart dose alone. Advanced cardiac imaging, cardiovascular risk assessment, and potentially even biomarkers can help guide patient care post-radiotherapy. In addition, treatment of ventricular arrhythmias with ablative radiotherapy may inform knowledge of radiation-induced cardiac dysfunction. Future efforts should explore further personalization of radiotherapy to minimize cardiac dysfunction by coupling knowledge derived from enhanced dosimetry to cardiac substructures, regional dysfunction post-radiation seen on advanced cardiac imaging, and more complete cardiac toxicity data.

JACC CardioOncology Editor-in-Chief and CME Editor
Bonnie Ky, MD, MSCE, FACC

Authors
Carmen Bergom, MD, PhD
Julie A. Bradley, MD
Juan Lopez-Mattei, MD, FACC
Joshua D. Mitchell, MD, FACC 

Important Dates

Date of Release: September 21, 2021   
Term of Approval/Date of CME/MOC/ECME Expiration: September 20, 2022 

Summary
Availability: On-Demand
Expires on Sep 20, 2022
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
1 ECME Credit
Android App Download IOS App Download Powered By